#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Asthma Dermatitis atopic Dementia Alzheimer's type Breast cancer metastatic Non-small cell lung cancer metastatic Type 2 diabetes mellitus More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    HER2 gene amplification Giant cell tumour of tendon sheath Rhabdoid tumour Short-bowel syndrome Adenoid cystic carcinoma Stargardt's disease Colitis ulcerative Ductal adenocarcinoma of pancreas Ichthyosis Diffuse large B-cell lymphoma recurrent Thalassaemia alpha Neuroendocrine carcinoma Myxoid liposarcoma Malignant fibrous histiocytoma Hypotransferrinaemia More trials…

    Learn about Rare Diseases

    Angiosarcoma – Basic Information Idiopathic pulmonary fibrosis – Life with Disease Short-bowel syndrome – Trials in Disease Aicardi-Goutieres syndrome – Treatment Glycogen storage disease type II Acute respiratory distress syndrome – Treatment Adrenogenital syndrome – Treatment Usher’s syndrome – Diagnostics Prolymphocytic leukaemia Langerhans’ cell histiocytosis – Trials in Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Farletuzumab Ecteribulin Rbl016.2 Pazopanib Atenolol SIPAVIBART Clascoterone Vibostolimab Gsk4011499 Idursulfase Namodenoson Diazepam Sodium Chloride Bempikibart Octreotide Hydrochloride Chlorphenamine Maleate Ifosfamide Guanfacine Infliximab Narsoplimab Resatorvid More therapies…

    Learn about Your Condition

    Diabetic foot Craniocerebral injury Rectosigmoid cancer BK virus infection White matter lesion Shock Friedreich's ataxia Ocular myasthenia Wiskott-Aldrich syndrome Biliary tract operation Apheresis Breast cancer stage IV Chronic coronary syndrome Hypervolaemia Osteoporosis postmenopausal More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Centre Hospitalier Victor Dupouy

Centre Hospitalier Victor Dupouy

6w Rud Db Lpjdrccxls Cqesjse Pklhupyf Ahbzkewnqzz 9ndjhw Fregia

Want to learn more about this study or check if you can participate? Contact us.

  • Prophylactic Tocilizumab to Prevent Cytokine Release Syndrome in Relapsed/Refractory Multiple Myeloma Patients Receiving JNJ-79635322 and Human Normal Immunoglobulin (IV)

    Recruiting

    2 1 1
    Investigated Drugs:
    • IGG1 TRISPECIFIC MONOCLONAL ANTIBODY AGAINST T-CELL RECEPTOR CD3, B-CELL MATURATION ANTIGEN AND G PROTEIN-COUPLED RECEPTOR CLASS C GROUP 5 MEMBER D
    • Human Normal Immunoglobulin (Iv)
    • Tocilizumab
    France Greece Hungary Portugal Spain Sweden

  • A study to compare the effectiveness of EL219 against liposomal amphotericin B and voriconazole for patients with suspected invasive mould infections.

    Recruiting

    2 1 1
    Investigated Diseases:
    • Fungal infection
    Investigated Drugs:
    • Amphotericin B
    • Amphotericine B, Liposome
    • Voriconazole
    Belgium France Italy Spain

  • A study testing prednisone combined with antibiotics compared to antibiotics alone in adults with septic arthritis to improve joint health

    Recruiting

    3 1 1
    Investigated Diseases:
    • Arthritis infective
    Investigated Drugs:
    • Prednisone
    France

  • A study comparing odronextamab combined with chemotherapy versus rituximab combined with chemotherapy in adults with previously untreated follicular lymphoma

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Prednisone
    • Cyclophosphamide
    • Doxorubicin Hydrochloride
    Austria Belgium Czechia France Germany Italy +2

  • Testing a Drug Combination for Personalized Sepsis Treatment in Children and Adults with Severe Blood Infection

    Recruiting

    2 1 1 1
    Investigated Drugs:
    • Fludrocortisone Acetate
    • Heparin
    • Human Plasma Protein
    France

  • Comparing lenalidomide and methotrexate for patients with difficult-to-treat cutaneous lupus erythematosus

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Lenalidomide
    • Methotrexate
    France

  • Study of ruxolitinib cream for children aged 6 to 12 years with non-segmental vitiligo

    Recruiting

    3 1
    Investigated Diseases:
    • Vitiligo
    Investigated Drugs:
    • Ruxolitinib
    Austria Belgium Bulgaria Denmark France Germany +6

  • Study on the Effectiveness and Safety of Tagraxofusp and Venetoclax for Adults with Untreated Blastic Plasmacytoid Dendritic Cell Neoplasm

    Recruiting

    2 1 1 1
    Investigated Drugs:
    • TAGRAXOFUSP
    • Venetoclax
    France

  • Study of elranatamab and lenalidomide combination versus standard chemotherapy and transplant in newly diagnosed multiple myeloma patients

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Lenalidomide
    • Bortezomib
    • Daratumumab
    Belgium France

  • Study on Preventing Infections in ICU Patients with Interferon Gamma and Sodium Chloride

    Recruiting

    3 1 1
    Investigated Drugs:
    • Recombinant Human Interferon Gamma 1B
    • Sodium Chloride
    France
1 2 3 … 9
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!